By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.




CEO: Ed Kaye, M.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT


Company News
Journalist Sues FDA for Documents Related to Sarepta (SRPT)'s DMD Drug 5/26/2017 6:22:15 AM
Can Sarepta (SRPT) Continue To Live Up To The DMD Hype? 5/8/2017 6:36:32 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 5/2/2017 11:57:43 AM
Sarepta (SRPT) Tests Biotech's CEO Vacuum Hypothesis 5/2/2017 6:11:09 AM
How Much Rumored Suitors Like Sanofi (SNY) Would Have To Pay For Sarepta (SRPT) 5/2/2017 6:10:29 AM
Why M&A Hungry Sanofi (SNY) Could be Gearing Up to Buy Sarepta (SRPT) 5/1/2017 6:09:23 AM
Here's Why Sarepta (SRPT) May Be The Rarest Of Finds: A 'Value' Biotech Stock 5/1/2017 5:48:09 AM
M&A Speculation Begins as Sarepta (SRPT) CEO Puts in His Notice 4/28/2017 5:46:36 AM
Sarepta (SRPT) To Announce First Quarter 2017 Financial Results And Recent Corporate Developments On April 27, 2017 4/17/2017 8:11:37 AM
Sarepta (SRPT) CEO Gives CMO Role to Former Amgen (AMGN)-Regeneron (REGN) Alum 4/4/2017 5:55:39 AM